Objective: This inpatient, randomised, three-way crossover study evaluated the steady-state pharmacokinetics and tolerability of generic clozapine (Creighton) versus Clozaril® (Novartis brand of clozapine) in patients with schizophrenia.
Setting: Patients were hospitalised throughout the study.
Patients: Thirty patients meeting DSM-III-R criteria for a diagnosis of schizophrenia participated in this study.
Design: Clozaril® was titrated over 5 days from 12.5 to 75mg twice daily, after which patients received all of the following 1-week regimens in random order: Clozaril® — one 100mg tablet twice daily; clozapine — four 25mg tablets twice daily; and clozapine — one 100mg tablet twice daily.
Main Outcome Measures and Results: Both the 25 and 100mg dose forms of clozapine were bioequivalent to Clozaril® 100mg, justifying their interchange-ability; mean area under the concentration-time curve (AUC0–12) values were 2683 ± 1613, 2781 ± 1775, and 2547 ± 1429 μg/L·h, respectively. The most common adverse events were dizziness and asthenia. Tolerability findings between groups were comparable, although a high incidence (20%) of symptomatic orthostatic hypotension during the initial titration of Clozaril® emphasised the need for careful monitoring, even in the target patient population.
Conclusions: The results of this study demonstrated that the 25 and 100mg dose forms of generic clozapine and Clozaril® 100mg are bioequivalent, which should ensure comparable efficacy and tolerability with the clinical use of either product.
Schizophrenia Adis International Limited Clozapine Schizophrenic Patient Bioequivalence Study
This is a preview of subscription content, log in to check access
Kane JM, Schooler NR, Marder SR, et al. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. In: Prien RF, Robinson DS, editors. Clinical evaluation of psychotropic drugs. New York: Raven Press, 1994: 345–72Google Scholar
Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148(2): 231–5PubMedGoogle Scholar
Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38(5): 471–3PubMedCrossRefGoogle Scholar
Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1c receptor antagonists. Eur J Pharmacol 1996; 245(2): 179–82Google Scholar
Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55 Suppl. B: 133–6PubMedGoogle Scholar
VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153(12): 1579–84PubMedGoogle Scholar
Miller AL, Maas JW, Contreras S, et al. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993; 34: 178–87PubMedCrossRefGoogle Scholar
Gelijns AC. Modern methods of clinical investigation. Washington, DC: National Academy Press, 1990Google Scholar
Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994; 11(8): 1221PubMedCrossRefGoogle Scholar
Food and Drug Administration. FDA update on clozapine guidelines. Rockville, MD, 1996Google Scholar
American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington, DC: American Psychiatric Press, 1987Google Scholar
Kay SR, Fizbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76PubMedGoogle Scholar
Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4(5): 402–5PubMedCrossRefGoogle Scholar
Physician’s Desk Reference. 51st ed. Montvale: Medical Economics Company, 1997: 2377Google Scholar
Choc MG, Hsuan F, Honigfeld G, et al. Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7(4): 347–51PubMedCrossRefGoogle Scholar
Cheng YF, Lundberg T, Bondesson U, et al. Clinical pharmacokinetics of clozapine in chronic schizophrenia patients. Eur J Clin Pharmacol 1988; 34(5): 445–9PubMedCrossRefGoogle Scholar
Carpenter Jr WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152(6): 827–32PubMedGoogle Scholar
Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40(4): 253–8PubMedCrossRefGoogle Scholar
Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153(6): 759–64PubMedGoogle Scholar
Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992; 4(2): 187–95PubMedCrossRefGoogle Scholar
Chacko RC, Hurley RA, Harper RG, et al. Clozapine for acute and maintenance treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1995; 7(4): 471–5PubMedGoogle Scholar
Safferman AZ, Kane JM, Aronowitz JS, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994; 55 Suppl. B: 98–101PubMedGoogle Scholar
Sramek JJ, Fresquet A, Marion-Landais G, et al. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol 1996; 16(6): 454–8PubMedCrossRefGoogle Scholar
Grof P, Akhter MI, Campbell M, et al. Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines. Seattle: Hogrefe & Huber, 1993Google Scholar
Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer’s disease. J Clin Pharmacol 1995; 35(8): 800–6PubMedGoogle Scholar
Goldberg MR, Barchowsky A, McCrea J, et al. Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteers study [abstract]. Second International Springfield Symposium on Advances in Alzheimer Therapy; 1991 May. Springfield, IL, USAGoogle Scholar
Sramek JJ, Sedman AF, Reece PA, et al. Safety and tolerability of CI-979 in patients with Alzheimer’s disease. Life Sci 1995; 57(5): 503–10PubMedCrossRefGoogle Scholar
Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer’s patients: the bridging study. Eur J Clin Pharmacol 1995; 48(6): 421–8PubMedCrossRefGoogle Scholar
Cutler NR, Sramek JJ. The target population in phase I clinical trials of cholinergic compounds in Alzheimer’s disease: the role of the ‘bridging study.’ Alzheimer Dis Assoc Disord 1995; 9: 139–45Google Scholar